OGXI 2.09 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week low of 2.08 Closing the day 10:42 at 2.09 -0.01 -0.48% With a day low of 2.08 and a total volume of 35,341.
OGXI Recent Posts: http://investorshangout.com/Oncogenex-Pharmac...GXI-54968/
OGXI Oncogenex Pharmaceuticals Inc Recent Headline News
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CNW Group - Mon Nov 17, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:55 a.m. ET at the New York Palace Hotel in New York City. The presentation will include an overview of apatorsen Phase 2 development plans, as well as additional data from custirsen Phase 3 SYNERGY exploratory analyses.
OGXI: 2.07 (-0.03)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 302.05 (-1.56), ALNY: 89.21 (-0.36), ISIS: 51.59 (+1.53), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05), RGLS: 15.59 (-0.67), GSK: 46.43 (+0.18), SNY: 46.98 (-1.11)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.30 (+0.02), PCYC: 138.53 (-0.07), CLDX: 20.94 (+2.21), INCY: 71.85 (+0.55), BIND: 7.78 (-0.62), CELG: 107.77 (+0.79), OMER: 21.48 (+0.51), VSTM: 8.74 (-0.07), GILD: 102.72 (+0.38), OGXI: 2.07 (-0.03), ANTH: 1.84 (-0.01), NVAX: 5.01 (+0.17)
OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST
OGXI: 2.07 (-0.03)
More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT
OGXI: 2.07 (-0.03)
OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT
OGXI: 2.07 (-0.03)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE
RL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In...
OGXI: 2.07 (-0.03), MCGC: 3.69 (unch), INVN: 15.42 (+0.28), DRL: 5.35 (+0.09), ARCP: 9.09 (+0.32)
OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT
OGXI: 2.07 (-0.03)
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.07 (-0.03)
OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 47.02 (+0.18), ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.78 (-0.02), ANY: 8.00 (-0.39), OGXI: 2.07 (-0.03), GLYC: 8.19 (+0.41)
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.07 (-0.03), ARTX: 2.30 (+0.06), CYTR: 2.57 (-0.06), CNCE: 12.74 (-0.07)
OncoGenex's Custirsen Passes First Interim Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:40PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the IDMC has recommended the continuation of the phase III ENSPIRIT study on custirsen for lung cancer.
ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), UTHR: 128.79 (+0.79), TEVA: 57.30 (+0.05)
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
PR Newswire - Thu Aug 21, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
OGXI Recent Posts: http://investorshangout.com/Oncogenex-Pharmac...GXI-54968/
OGXI Oncogenex Pharmaceuticals Inc Recent Headline News
OncoGenex Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
CNW Group - Mon Nov 17, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Stifel 2014 Healthcare Conference on Wednesday, November 19, 2014 at 10:55 a.m. ET at the New York Palace Hotel in New York City. The presentation will include an overview of apatorsen Phase 2 development plans, as well as additional data from custirsen Phase 3 SYNERGY exploratory analyses.
OGXI: 2.07 (-0.03)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 302.05 (-1.56), ALNY: 89.21 (-0.36), ISIS: 51.59 (+1.53), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05), RGLS: 15.59 (-0.67), GSK: 46.43 (+0.18), SNY: 46.98 (-1.11)
Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.30 (+0.02), PCYC: 138.53 (-0.07), CLDX: 20.94 (+2.21), INCY: 71.85 (+0.55), BIND: 7.78 (-0.62), CELG: 107.77 (+0.79), OMER: 21.48 (+0.51), VSTM: 8.74 (-0.07), GILD: 102.72 (+0.38), OGXI: 2.07 (-0.03), ANTH: 1.84 (-0.01), NVAX: 5.01 (+0.17)
OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST
OGXI: 2.07 (-0.03)
More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT
OGXI: 2.07 (-0.03)
OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT
OGXI: 2.07 (-0.03)
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE
RL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In... OGXI: 2.07 (-0.03), MCGC: 3.69 (unch), INVN: 15.42 (+0.28), DRL: 5.35 (+0.09), ARCP: 9.09 (+0.32)
OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT
OGXI: 2.07 (-0.03)
OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.07 (-0.03)
OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 47.02 (+0.18), ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.78 (-0.02), ANY: 8.00 (-0.39), OGXI: 2.07 (-0.03), GLYC: 8.19 (+0.41)
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.07 (-0.03), ARTX: 2.30 (+0.06), CYTR: 2.57 (-0.06), CNCE: 12.74 (-0.07)
OncoGenex's Custirsen Passes First Interim Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:40PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the IDMC has recommended the continuation of the phase III ENSPIRIT study on custirsen for lung cancer.
ENDP: 69.30 (+0.29), OGXI: 2.07 (-0.03), UTHR: 128.79 (+0.79), TEVA: 57.30 (+0.05)
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
PR Newswire - Thu Aug 21, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.
OGXI: 2.07 (-0.03), TEVA: 57.30 (+0.05)
